The representation of female oncologists in leadership roles – ESMO
ESMO (European Society for Medical Oncology) shared a post on LinkedIn:
”ESMO24: The ESMO Women for Oncology Committee has been actively monitoring the representation of emale oncologists in leadership roles since 2015. Despite progress in some areas, the representation of women in oncology leadership remains low, particularly at congresses, on society boards, and as leading authors in publications.
Helena Linardou will dive deeper in findings from this work on Monday, 16 September at 14:45 during the Policy and preventive strategies Mini Oral session. We encourage all delegates to attend for additional insights.”
Source: ESMO/LinkedIn
The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up. It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.
Helena Linardou is the Director of the 4th Oncology Department and the Comprehensive Clinical Trials Center at Metropolitan Hospital, where she leads efforts in the diagnosis, treatment, and research of various cancers, with a particular focus on lung cancer. She is committed to advancing oncology through translational medicine, with a strong emphasis on biomarker-driven patient management.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023